- CENTRALIZED PROTOCOL AND DATA MANAGEMENT The Centralized Protocol and Data Management Unit (CPDMU) provides centralized infrastructure, coordination, and support for cancer clinical trials at the Albert Einstein Cancer Center (AECC), a component of the Montefiore Health System (MHS). CPDMU supports the Protocol Review and Monitoring System (PRMS) and Data Safety Monitoring Committee (DSMC), and the scientific activities of the AECC Experimental Therapeutics (ET) Program. The CPDMU, with an annual operating budget of $4.5 million, includes 35 FTEs who support 80 faculty PIs. MHS has substantially increased 3 operational managers focused on administration and data investment in CPDMU (from $266,220 in 2017 to $570,913 projected for 2018). The Velos-based Clinical Trials/Research Management System (CTRMS) was launched in 2015. The CPDMU has been restructured with faculty member management - J. Sparano, MD director, S. Goel, MD (co-director for protocol development), T. Ow, MD (co-director for protocol support), and B. Halmos, MD (Co-director for precision medicine and immunotherapy). During the last funding period (7/1/13-6/30/18), overall intervention accruals increased by 22% and intervention national trial accrual increased 2.1-fold. Based on 2017, in tumor registry data reflected in Data Table 3, 10.8% of patients were enrolled on intervention trials, and more than 80% of trial participants were Hispanic or African-American. During the last 3-years (7/1/15-6/30/18), there were 442 new protocols activated, including 306 intervention (15% institutional) and 136 non-intervention (85% institutional). The CPDMU also supports participation as a Minority Underserved NCORP, reflecting a major commitment to the NCTN (23% of new therapeutic trials and 32% of therapeutic accruals last year). Major new initiatives include NCI-funded trials in breast cancer screening (EA1151-TMIST), anal cancer screening/treatment (ANCHOR), and tissue collection in minorities with cancer (DCP-002, P9846).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013330-48
Application #
9998895
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2022-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
48
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Type
DUNS #
081266487
City
Bronx
State
NY
Country
United States
Zip Code
10461
Mao, Serena P H; Park, Minji; Cabrera, Ramon M et al. (2018) Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth. Breast Cancer Res 20:131
Mocholi, Enric; Dowling, Samuel D; Botbol, Yair et al. (2018) Autophagy Is a Tolerance-Avoidance Mechanism that Modulates TCR-Mediated Signaling and Cell Metabolism to Prevent Induction of T Cell Anergy. Cell Rep 24:1136-1150
Yang, Chia-Ping Huang; Wang, Changwei; Ojima, Iwao et al. (2018) Taxol Analogues Exhibit Differential Effects on Photoaffinity Labeling of ?-Tubulin and the Multidrug Resistance Associated P-Glycoprotein. J Nat Prod 81:600-606
Guan, Fangxia; Tabrizian, Tahmineh; Novaj, Ardijana et al. (2018) Dietary Walnuts Protect Against Obesity-Driven Intestinal Stem Cell Decline and Tumorigenesis. Front Nutr 5:37
Wang, Tao; Hosgood, H Dean; Lan, Qing et al. (2018) The Relationship Between Population Attributable Fraction and Heritability in Genetic Studies. Front Genet 9:352
Chennamadhavuni, Divya; Saavedra-Avila, Noemi Alejandra; Carreño, Leandro J et al. (2018) Dual Modifications of ?-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity. Cell Chem Biol 25:571-584.e8
Limi, Saima; Senecal, Adrien; Coleman, Robert et al. (2018) Transcriptional burst fraction and size dynamics during lens fiber cell differentiation and detailed insights into the denucleation process. J Biol Chem 293:13176-13190
Rocha, Agostinho G; Franco, Antonietta; Krezel, Andrzej M et al. (2018) MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science 360:336-341
Cabahug-Zuckerman, Pamela; Stout Jr, Randy F; Majeska, Robert J et al. (2018) Potential role for a specialized ?3 integrin-based structure on osteocyte processes in bone mechanosensation. J Orthop Res 36:642-652
Vilchèze, Catherine; Copeland, Jacqueline; Keiser, Tracy L et al. (2018) Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. MBio 9:

Showing the most recent 10 out of 1508 publications